Search

Your search keyword '"Konecny, G.E."' showing total 43 results

Search Constraints

Start Over You searched for: Author "Konecny, G.E." Remove constraint Author: "Konecny, G.E."
43 results on '"Konecny, G.E."'

Search Results

3. Prognostic gene expression signature for high-grade serous ovarian cancer

9. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

10. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

11. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

13. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate

15. Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

17. Prognostic gene expression signature for high-grade serous ovarian cancer

18. 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort

19. Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

20. PARPi after PARPi in epithelial ovarian cancer

23. Population exposure-safety and exposure-efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2

27. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2

30. 1002P - Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

34. Phase 2 Study of Second-Line Dovitinib (Tki258) in Patients with Fibroblast Growth Factor Receptor 2 (Fgfr2)-Mutated or -Nonmutated Advanced and/or Metastatic Endometrial Cancer

35. Preliminary Results of Ariel2, a Phase 2 Open-Label Study to Identify Ovarian Cancer Patients Likely to Respond to Rucaparib

36. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

37. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

38. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

39. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

43. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer.

Catalog

Books, media, physical & digital resources